Bharat Parenterals Limited share price
Bharat Parenterals Limited engages in the research, development, manufacturing, marketing, sourcing, and distribution of pharmaceutical products in India and internationally. The company provides antibiotics, cardiovascular and central nervous system, antifungal, antimalarial, gastrointestinal tract/alimentary systems, analgesics, anaesthetics, quinolones, erectile dysfunction medicines, nutritional supplements, steroids and hormones, and other drugs. It also engages in manufacturing general products in capsules, tablets, ointment and creams, injections, oral liquids, and powder sachets forms; and beta lactum and cephalosporin products in capsules, tablets, dry syrup, and powder for injecti…Read more
- Market Cap₹ 1,243 Cr.
- Current Price₹ 1,804.00
- High / Low₹ 2,278 / 1,201
- Stock P/E—
- Book Value₹ 796
- Dividend Yield0.05 %
- ROCE-2.2 %
- ROE-2.50 %
- Face Value—
More figures (10)
- EPS (TTM)₹ -38.41
- Price / Book2.27
- OPM-5.4 %
- Debt / Equity0.45
- Sales growth (3Y)16.4 %
- Profit growth (3Y)—
- Promoter holding79.7 %
- EV / EBITDA133.2
- Beta0.72
- All-time high₹ 2,278
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| BPLPHARMA | +19.49% | — | — | — | — | — | — |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Bharat Parenterals Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹1,243 crore.
- Revenue grew 16.4% a year over the last 3 years.
- Return on equity was -2.5% and return on capital employed -2.2% in the latest year.
- Debt was 0.45 times shareholders' equity.
- The share price is 20.8% below its 52-week high.
- Promoters and insiders hold about 79.7%; institutions about 0.1%.
Pros
AINo standout strengths in the reported figures.
Cons
AI- Return on equity has been low: 0.1% on average over the last 3 years.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Bharat Parenterals Limited
Bharat Parenterals Limited engages in the research, development, manufacturing, marketing, sourcing, and distribution of pharmaceutical products in India and internationally. The company provides antibiotics, cardiovascular and central nervous system, antifungal, antimalarial, gastrointestinal tract/alimentary systems, analgesics, anaesthetics, quinolones, erectile dysfunction medicines, nutritional supplements, steroids and hormones, and other drugs. It also engages in manufacturing general products in capsules, tablets, ointment and creams, injections, oral liquids, and powder sachets forms; and beta lactum and cephalosporin products in capsules, tablets, dry syrup, and powder for injection forms. In addition, it offers research, development and manufacture of pharmaceutical formula ons, including sterile injectable products, oral liquid formula ons, prefilled syringes, other specialt…
- Employees
- 404
- Head office
- Vadodara
Peer comparison
HealthcareDrug Manufacturers - Specialty & Generic
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Bharat Parenterals | 1,804.00 | — | 1,243 | 0.05 | 1 | -87.75 | 94 | -19.19 | -2.2 | -2.5 | 2.27 | -5.4 | 0.45 | 79.74 | 343 | 16.4 |
| 2. | Sun Pharmaceutical Industries | 1,758.80 | 34.9 | 4,21,995 | 0.91 | 2,895 | 34.65 | 15,184 | 18.48 | 17.9 | 14.7 | 5.05 | 23.4 | 0.06 | 55.61 | 58,220 | 10.4 |
| 3. | Divi's Laboratories | 9,144.50 | 83.0 | 2,42,758 | 0.33 | 902 | 36.25 | 3,080 | 19.15 | 19.0 | 16.2 | 14.48 | 28.4 | 0.00 | 52.00 | 10,476 | 11.0 |
| 4. | Torrent Pharmaceuticals | 4,558.90 | 72.8 | 1,73,406 | 0.83 | 566 | 3.28 | 4,835 | 54.57 | 9.1 | 27.1 | 18.39 | 25.0 | 1.79 | 63.18 | 13,753 | 13.3 |
| 5. | Zydus Lifesciences | 1,123.00 | 25.0 | 1,12,020 | 0.09 | 940 | -19.74 | 7,802 | 24.03 | 19.0 | 19.7 | 4.17 | 21.7 | 0.46 | 75.18 | 26,720 | 16.5 |
| 6. | Laurus Labs | 2,060.10 | 101.8 | 1,11,310 | 0.12 | 362 | 123.94 | 2,026 | 29.10 | 19.5 | 18.2 | 20.98 | 19.4 | 0.48 | 32.03 | 6,813 | 3.8 |
| 7. | Cipla | 1,325.10 | 31.8 | 1,07,051 | 0.98 | 789 | -35.42 | 7,077 | 7.26 | 14.9 | 11.8 | 3.11 | 17.5 | 0.02 | 31.13 | 27,712 | 7.2 |
| 8. | Dr. Reddy's Laboratories | 1,233.00 | 31.0 | 1,02,707 | 0.66 | 444 | -68.72 | 8,071 | -5.56 | 14.2 | 12.1 | 2.68 | 14.9 | 0.21 | 30.14 | 33,593 | 11.0 |
| 9. | Abbott India | 26,170.00 | 34.4 | 55,609 | 2.01 | 429 | 17.13 | 1,814 | 4.33 | 41.9 | 34.5 | 11.65 | 26.3 | 0.04 | 75.54 | 6,927 | 9.0 |
| 10. | Ipca Laboratories | 1,832.60 | 35.5 | 46,494 | 0.31 | 424 | 82.18 | 2,788 | 20.76 | 16.4 | 15.2 | 5.77 | 17.0 | 0.10 | 45.06 | 9,646 | 15.5 |
| Median: 14 Co. | 1,818.30 | 34.4 | 79,158 | 0.67 | 505 | 10.21 | 3,958 | 18.81 | 17.2 | 16.5 | 5.41 | 20.6 | 0.16 | 53.81 | 12,114 | 11.0 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
| ₹ Cr | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Sales | 116 | 65 | 65 | 100 | 94 |
| Operating Profit | 5 | -8 | -7 | -9 | -0 |
| Profit before tax | 3 | -7 | -8 | -8 | -1 |
| Net Profit | 8 | -7 | -5 | -5 | 1 |
| EPS in Rs | 11.94 | -14.00 | -14.03 | -11.84 | 1.46 |
Profit & Loss
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 218 | 257 | 335 | 343 |
| Operating Profit | 16 | 18 | -31 | -18 |
| Interest | 2 | 3 | 12 | 11 |
| Depreciation | 6 | 9 | 35 | 34 |
| Profit before tax | 24 | 19 | -34 | -21 |
| Net Profit | 16 | 15 | -13 | -8 |
| EPS in Rs | 28.40 | 24.94 | -19.26 | -11.88 |
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 6 | 6 | 7 | 7 |
| Reserves | 177 | 191 | 324 | 315 |
| 50 | 158 | 180 | 146 | |
| Long term borrowings | 11 | 73 | 76 | 122 |
| Short term borrowings | 39 | 84 | 104 | 24 |
| 118 | 149 | 138 | 145 | |
| Trade payables | 51 | 59 | 74 | 64 |
| Minority interest | 35 | 41 | 8 | -11 |
| Current liabilities | 120 | 190 | 222 | 157 |
| Total Liabilities | 350 | 504 | 649 | 613 |
| 161 | 238 | 236 | 241 | |
| Gross block | 200 | 284 | 307 | 345 |
| Accumulated depreciation | 39 | 46 | 71 | 104 |
| Goodwill & intangibles | 1 | 53 | 54 | |
| CWIP | 120 | 28 | 37 | 40 |
| 70 | 238 | 375 | 332 | |
| Inventories | 38 | 61 | 72 | 85 |
| Trade receivables | 112 | 141 | 172 | 151 |
| Cash & equivalents | 8 | 9 | 1 | 1 |
| Current assets | 184 | 262 | 356 | 310 |
| Total Assets | 350 | 504 | 649 | 613 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 22 | -5 | -27 | 38 | |
| Profit for the year | 16 | 15 | -13 | -8 |
| Working capital changes | -2 | -29 | -23 | 21 |
| Direct taxes paid | -9 | -9 | -11 | -10 |
| -78 | -105 | -137 | 9 | |
| Fixed assets purchased | -92 | -104 | -29 | -40 |
| Fixed assets sold | 2 | 1 | 0 | 0 |
| Investments purchased | -5 | -1 | ||
| Investments sold | 47 | |||
| 61 | 110 | 156 | -47 | |
| Proceeds from borrowings | 62 | 3 | 46 | |
| Repayment of borrowings | -1 | |||
| Interest paid | -2 | -3 | -13 | -12 |
| Dividends paid | -0 | -1 | -1 | |
| Net Cash Flow | 4 | 1 | -8 | 1 |
| Free Cash Flow | -70 | -109 | -56 | -2 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROE | 9.0% | 7.6% | -4.8% | -2.5% |
| ROCE | 11.2% | 7.0% | -5.2% | -2.2% |
| Operating margin | 7.2% | 7.0% | -9.2% | -5.4% |
| Net margin | 7.6% | 5.6% | -3.8% | -2.4% |
| Debt / equity | 0.27 | 0.80 | 0.54 | 0.45 |
| Current ratio | 1.54 | 1.38 | 1.60 | 1.97 |
| Debtor days | 189 | 201 | 187 | 160 |
| Inventory days | 95 | 133 | 124 | 151 |
| Days payable | 129 | 129 | 128 | 114 |
| Cash conversion cycle | 155 | 205 | 183 | 197 |
| Working capital days | 108 | 102 | 145 | 162 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
- Promoters & insiders 79.74%
- Institutions (FII, DII, funds) 0.07%
- Public & others 20.19%
Key dates
- Ex-dividend date
- 11 Sep 2026
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
In the news
From the company (NSE)
No recent announcements.
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about Bharat Parenterals Limited
What is the share price of Bharat Parenterals Limited today?
What is the market cap of Bharat Parenterals Limited?
What is the P/E ratio of Bharat Parenterals Limited?
Is Bharat Parenterals Limited a good investment?
How can I buy Bharat Parenterals Limited shares?
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.